Patents by Inventor Franklin Volvovitz

Franklin Volvovitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130289021
    Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
    Type: Application
    Filed: March 29, 2013
    Publication date: October 31, 2013
    Inventor: Franklin Volvovitz
  • Patent number: 8299062
    Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: October 30, 2012
    Inventor: Franklin Volvovitz
  • Publication number: 20120264741
    Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Inventor: Franklin Volvovitz
  • Publication number: 20090048234
    Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
    Type: Application
    Filed: September 17, 2004
    Publication date: February 19, 2009
    Inventor: Franklin Volvovitz
  • Publication number: 20080090808
    Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
    Type: Application
    Filed: October 17, 2006
    Publication date: April 17, 2008
    Inventor: Franklin Volvovitz
  • Patent number: 6951649
    Abstract: The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The improved composition can include and be administered with an adjuvant. The improved vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 4, 2005
    Assignee: Protein Sciences Corporation
    Inventors: Gail Eugene Smith, James T. Matthews, Edwin D Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrie I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Publication number: 20030165521
    Abstract: An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intermuscular, intravascular, and intravenous injections, are included.
    Type: Application
    Filed: October 4, 2002
    Publication date: September 4, 2003
    Inventors: Gale Eugene Smith, James T. Matthews, Edwin D. Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Patent number: 6485729
    Abstract: An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intramuscular, intravascular, and intravenous, are included.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: November 26, 2002
    Assignee: Protein Sciences Corporation
    Inventors: Gail Eugene Smith, James T. Matthews, Edwin D. Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Publication number: 20020071848
    Abstract: Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-microphage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, preferably three strains of the virus, and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present.
    Type: Application
    Filed: January 22, 1999
    Publication date: June 13, 2002
    Inventors: GALE EUGENE SMITH, BETHANIE E. WILKINSON, ANDREI I. VOZNESENSKY, FRANKLIN VOLVOVITZ, CRAIG S. HACKETT
  • Patent number: 6245532
    Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: June 12, 2001
    Assignee: Protein Sciences Corporation
    Inventors: Gale E. Smith, Franklin Volvovitz, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett
  • Patent number: 5976552
    Abstract: Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-microphage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, preferably three strains of the virus, and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 2, 1999
    Assignee: Protein Sciences Corporation
    Inventor: Franklin Volvovitz
  • Patent number: 5858368
    Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 12, 1999
    Assignee: Protein Sciences Corporation
    Inventors: Gale E. Smith, Franklin Volvovitz, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett
  • Patent number: 5762939
    Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a trivalent influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. The cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed which can be adapted for the purification of rHA proteins from A sub-types and B type influenza viruses.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: June 9, 1998
    Assignee: MG-PMC, LLC
    Inventors: Gale Eugene Smith, Franklin Volvovitz, Bethanie Eident Wilkinson, Craig Stanway Hackett